Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.

Details

Request a copyRequest a copy
Serval ID
serval:BIB_273D40DF2F09
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Production externe
Title
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
Journal
American journal of hematology
Author(s)
Delimpasi S., Mateos M.V., Auner H.W., Gavriatopoulou M., Dimopoulos M.A., Quach H., Pylypenko H., Hájek R., Leleu X., Dolai T.K., Sinha D.K., Venner C.P., Benjamin R., Garg M.K., Doronin V., Levy Y., Moreau P., Chai Y., Arazy M., Shah J., Shacham S., Kauffman M.G., Richardson P.G., Grosicki S.
ISSN
1096-8652 (Electronic)
ISSN-L
0361-8609
Publication state
Published
Issued date
01/03/2022
Peer-reviewed
Oui
Volume
97
Number
3
Pages
E83-E86
Language
english
Notes
Publication types: Letter ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Keywords
Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Bortezomib/administration & dosage, Dexamethasone/administration & dosage, Disease-Free Survival, Female, Humans, Hydrazines/administration & dosage, Kidney Diseases/drug therapy, Kidney Diseases/mortality, Male, Middle Aged, Multiple Myeloma/drug therapy, Multiple Myeloma/mortality, Survival Rate, Triazoles/administration & dosage
DOI
10.1002/ajh.26434
Pubmed
34882831
Web of science
000735411300001
Open Access
Yes
Create date
02/12/2024 16:49
Last modification date
04/12/2024 7:07
Usage data